ClinicalTrials.gg
CompletedNCT04613128Updated Apr 27, 2026

The PROMISE Pediatric Study 6 to 11 Years Old

An observational study in Cystic Fibrosis and Cystic Fibrosis in Children, sponsored by Nicole Hamblett. Completed at 20 sites in United States. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Nicole Hamblett · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
6 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
73rd of 193
125 · median 80
Started
2021
with 35 others
Observational
194 of 717
41 open now
Registered
563rd of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 73rd largest by enrollment of the 193 observational ones that give a count, is one of 36 that started in 2021, is one of 194 observational ones, and was the 563rd registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 6 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multi-center observational study. The study is designed to measure the clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination therapy in children (6-11 years of old) with one or more copies of the F508del mutation, study the effects of ETI across a number of CF disease manifestations, and collect specimens for future research. Subjects in the study will have one "before ETI" visit within 30 days before initiation of the therapy and five "after ETI" visits over a 24-month follow-up period. Participants who have participated in the original PROMISE Pediatric Sub-Study have the option of participating in a long-term extension with annual visits performed at the 36- and 48-month timepoints. The durability of the clinical and biological changes in the PROMISE Pediatric Sub-Study can be assessed with extended follow-up, which would enable the sub-studies to consider potential clinical consequences of the biological or physiological effects being studied. This work will help to inform long term prognosis and feasibility of certain clinical trials outcomes for interventional studies and may be useful when considering research priorities in drug development. The duration of participation for each subject is 24 months (with an additional 24 months if participants agree to the optional long-term extension). NOTE: FDA has granted approval for elexacaftor, tezacaftor and ivacaftor in the 6-11 age group.

Read the detailed description

While nearly 2000 mutations have been described, the most common disease causing CFTR mutation is F508del, which is found in >85% of patients followed in the US CF Patient Registry. Two CFTR corrector drugs (elexacaftor and tezacaftor) plus the potentiator ivacaftor have been developed and approved as a triple combination therapy for CF patients (12 years old and above) with one or two copies of the F508del mutation. We predict that over 90% of pediatric CF patients (age 6-11 y/o) will be eligible for highly effective CFTR modulator therapy in the U.S.

The PROMISE Pediatric Study is designed to measure the direct and indirect CFTR dependent anion secretion by collecting and analyzing clinical research outcomes and biomarkers on pediatric patients both before and after they begin treatment with ETI. This study will investigate the impact of ETI across a wide range of CF disease manifestations and organ systems. While specific biomarkers of special interest have been selected for detailed analysis in this study, an additional important goal is to collect blood, urine, stool, and airway epithelial cell specimens for long-term storage in a biorepository to enable future research. These samples can be made available for research beyond the current scope of work. The PROMISE Pediatric Study will provide a coordinated collection of clinical research outcomes data that can be linked with these specimens.

03

Conditions studied

  • Cystic Fibrosis
  • Cystic Fibrosis in Children

Browse trials for

Keywords

  • CF
  • Cystic Fibrosis
  • CFTR Modulator
  • Trikafta
  • Triple Combination Therapy
  • Pediatric
  • ETI
  • elexacaftor/texacaftor/ivacaftor
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cystic Fibrosis, 6-11 years old prescribed ETI.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written parental and assent obtained from subject and the subject's legal guardian.
  2. Be willing and able to adhere to the study visit schedule and other protocol requirements.
  3. All genders 6-11 years old on Day 1.
  4. Diagnosis of CF.
  5. CFTR mutations consistent with the FDA labeled indication for the ETI.
  6. Physician intent to prescribe the ETI.
  7. Able to attempt the testing and procedures required for this study, as judged by the investigator.
  8. Enrolled in the Cystic Fibrosis Foundation Patient Registry.
  9. Clinically stable with no significant changes in health status within the 14 days prior to Visit 1 (and inclusive of Visit 1).

Exclusion criteria

Exclusion Criteria:

  1. Has any other condition that, in the opinion of the Site Investigator/designee, would preclude or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
  2. Use of any ETI within the 180 days prior to Visit 1.
  3. Any acute use of antibiotics (oral, inhaled or IV) or acute use of systemic within the 14 days prior to Visit 1 (inclusive of Visit 1) for lower respiratory tract symptoms.
  4. Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, inhaled tobramycin, Cayston®, Kalydeco, Orkambi®, Symdeko®) within the 4 weeks prior to Visit 1 (inclusive of Visit 1).
  5. Use of an agent within the 28 days prior to Visit 1.
  6. Use of chronic oral corticosteroids (equivalent to 10 mg. or more per day of prednisone) within the 28 days prior to Visit 1.
  7. Treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two antibiotics (oral, IV, and/or inhaled) within the 28 days prior to Visit 1.
  8. History of lung or liver transplantation,or listing for organ transplantation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Pediatric

    Cystic Fibrosis pediatric patients (6-11 years old) prescribed ETI CFTR modulator Therapy.

06

What researchers measure

Primary outcomes

  1. Sweat Chloride at 6 months

    Change in sweat chloride from Baseline to 6 months.

    Time frame: 6 months

  2. Sweat Chloride at 24 months

    Change sweat chloride from Baseline to 24 months.

    Time frame: 24 months

  3. Forced expiratory volume at one second (FEV1) at 6 months

    Change in FEV1 from Baseline to 6 months.

    Time frame: 6 months

  4. Forced expiratory volume at one second (FEV1) at 24 months

    Change in FEV1 from Baseline to 24 months.

    Time frame: 24 months

  5. Lung Clearance Index (LCI) at 6 months

    Change Lung Clearance Index (LCI) from baseline to 6 months.

    Time frame: 6 months

  6. Lung Clearance Index (LCI) at 24 months

    Change Lung Clearance Index (LCI) from baseline to 24 months.

    Time frame: 24 months

Secondary outcomes

  1. Weight at 6 Months

    Change in weight from Baseline to 6 months.

    Time frame: 6 months

  2. Weight at 24 Months

    Change in weight from Baseline to 24 months.

    Time frame: 24 months

  3. BMI at 6 Months

    Change in BMI from Baseline to 6 months.

    Time frame: 6 months

  4. BMI at 24 Months

    Change in BMI from Baseline to 24 months.

    Time frame: 24 months

  5. Cystic Fibrosis Questionnaire Revised (CFQ-R) at 6 Months

    Change in CFQ-R (respiratory domain) from Baseline to 6 months.

    Time frame: 6 months

  6. Cystic Fibrosis Questionnaire Revised (CFQ-R) at 24 Months

    Change in CFQ-R (respiratory domain) from Baseline to 24 months.

    Time frame: 24 months

07

Study locations

20 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • John Hopkins University
    Baltimore, Maryland 21287, United States
  • Boston Children's Hospital, Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • The Minnesota Cystic Fibrosis Center
    Minneapolis, Minnesota 55455, United States
  • Children's Mercy Kansas City
    Kansas City, Missouri 64108, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44146, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Wisconsin
    Madison, Wisconsin 53792, United States
  • Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Dec 2025, 53 months.

Of 228 non-industry observational studies under Cystic Fibrosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 89. This study's 53 months is above that.

Counting every sponsor, half of 243 studies reached it within 41 months; a quarter within 19 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2020
First posted
Nov 3, 2020
StartActual
Jun 11, 2021
Primary completionActual
Dec 8, 2025
CompletionActual
Dec 8, 2025
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04613128
Lead sponsor
Nicole Hamblett
Collaborators
Cystic Fibrosis Foundation
Responsible party
Nicole Hamblett (Professor of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington School of Medicine Adjunct Professor, Biostatistics, University of Washington School of Medicine Co-Executive Director, Cystic Fibrosis Therapeutics Development, Seattle Children's Hospital) — Sponsor-investigator
First posted
Nov 3, 2020
Start date
Jun 11, 2021
Primary completion
Dec 8, 2025
Completion
Dec 8, 2025
Last update
Apr 27, 2026

Study contacts

Steven Rowe, MD
principal investigator · University of Alabama at Birmingham
David Nichols, MD
principal investigator · University of Washington

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion